Market News AIOpen the app

CDT Equity has started testing its tapinarof combinations with QIMA Life Sciences to treat vitiligo.

DealRead the original at globenewswire.com
Good for CDT

CDT has begun early testing of its vitiligo drug combinations. The work may help it seek a licensing deal, but no study results or deal are reported.

CDT · CDT Equity Inc.

AI read · Good for CDT

The AI's read

The work may give CDT evidence to show companies that could license the treatments. That could help move the combinations toward wider use. But this is still early testing with skin samples. No study results or licensing deal were announced, so the benefit is not yet proven.

Get alerts for CDT

Follow CDT Equity Inc. (CDT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CDT
Free on the App Store and Google Play, or on the web.